You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

CLINICAL TRIALS PROFILE FOR HYALURONIDASE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Hyaluronidase

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01839487 ↗ PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Completed Halozyme Therapeutics Phase 2 2013-05-14 This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) [PAG] to NAB and GEM [AG] in participants with Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). The study will have 2 run-in phases, one for each formulation of PEGPH20 (original and new formulations), and a Phase 2 portion. The 2 run-in phases will evaluate the safety and tolerability of the PAG treatment using the original and new succinic acid PEGPH20 formulation, respectively, compared with AG treatment. Phase 2 will have 2 stages due to a partial clinical hold that occurred from April through July 2014. The participants will be randomized in 3:1 for the run-in phases. The first stage will randomize participants in a 1:1 ratio. The second stage will randomize participants in a 2:1 ratio (PAG:AG). This is an open-label study. To minimize bias to the progression-free survival endpoint, disease progression will be based on the assessment of the Central Imaging Reader (CIR). Determination of clinical progression by the Investigator without corresponding CIR confirmation will be documented with the relevant signs and symptoms.
New Formulation NCT05388669 ↗ A Study of Lazertinib and Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer Not yet recruiting Janssen Research & Development, LLC Phase 3 2022-08-05 The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Hyaluronidase

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000493 ↗ Multicenter Investigation of Limitation of Infarct Size (MILIS) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1977-09-01 To assess the ability of two separate therapeutic interventions, propranolol and hyaluronidase, to limit the ultimate size of an acute myocardial infarction. A secondary objective was to assess the influence of these therapies upon ventricular function and morbidity following myocardial infarction.
NCT00198419 ↗ Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Completed Bausch & Lomb Incorporated Phase 1 2004-03-01 The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable.
NCT00198458 ↗ Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Completed Bausch & Lomb Incorporated Phase 1 2004-07-01 The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to a 10% hypersensitivity response was considered acceptable.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hyaluronidase

Condition Name

Condition Name for Hyaluronidase
Intervention Trials
Type 1 Diabetes Mellitus 6
Healthy 6
Dehydration 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hyaluronidase
Intervention Trials
Diabetes Mellitus 12
Multiple Myeloma 10
Neoplasms, Plasma Cell 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hyaluronidase

Trials by Country

Trials by Country for Hyaluronidase
Location Trials
United States 436
United Kingdom 17
Spain 15
France 15
Brazil 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hyaluronidase
Location Trials
California 36
New York 22
Texas 20
Washington 19
North Carolina 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hyaluronidase

Clinical Trial Phase

Clinical Trial Phase for Hyaluronidase
Clinical Trial Phase Trials
Phase 4 16
Phase 3 20
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hyaluronidase
Clinical Trial Phase Trials
Completed 60
Recruiting 26
Not yet recruiting 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hyaluronidase

Sponsor Name

Sponsor Name for Hyaluronidase
Sponsor Trials
Halozyme Therapeutics 36
National Cancer Institute (NCI) 10
Baxter Healthcare Corporation 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hyaluronidase
Sponsor Trials
Other 90
Industry 82
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Hyaluronidase: Clinical Trials, Market Analysis, and Projections

Introduction to Hyaluronidase

Hyaluronidase is an enzyme that breaks down hyaluronic acid, a key component of the extracellular matrix. This enzyme has diverse applications, including cosmetic treatments, cancer therapy, and ophthalmic therapeutic solutions. Here, we will delve into recent clinical trials, market analysis, and projections for hyaluronidase.

Clinical Trials and Approvals

Multiple Myeloma Treatment

A significant recent development involves the FDA approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma in patients eligible for a stem cell transplant. This approval was based on the PERSEUS clinical trial, which showed a 60% lower risk of disease progression or death in the experimental arm compared to the control arm[1].

Subcutaneous Administration in Solid Tumors

Another notable approval is for nivolumab and hyaluronidase-nvhy, a PD-1 inhibitor co-formulated with recombinant human hyaluronidase (rHuPH20) for subcutaneous administration in patients with solid tumors. This formulation offers a faster and more convenient alternative to intravenous infusions, with consistent efficacy and comparable safety profiles[4].

Market Analysis

Current Market Size

The global hyaluronidase market was estimated at USD 909.5 million in 2022 and is projected to grow significantly over the next few years. By 2030, the market is expected to reach USD 2.62 billion at a CAGR of 14.43%[5].

Growth Drivers

Several factors are driving the growth of the hyaluronidase market:

  • Increasing Prevalence of Chronic Diseases: Conditions like cancer and diabetes lead to the accumulation of hyaluronic acid, making hyaluronidase a valuable treatment option[3].
  • Technological Advancements: The development of recombinant hyaluronidase has reduced the risk of allergic reactions, making the enzyme safer and more effective[3].
  • Strategic Collaborations: Partnerships between healthcare providers and biotech firms are fueling innovation in the hyaluronidase market[5].

Market Segments

  • Dermatology: This segment held the largest revenue share in 2022, with approximately 44.6% of the market. The increasing significance of hyaluronidase in dermatology is driving this segment's growth[2].
  • Chemotherapy: The chemotherapy segment is expected to register the fastest CAGR, driven by the enzyme's role in enhancing tumor response to chemotherapeutic drugs[2].

Market Projections

Forecasted Growth

By 2036, the hyaluronidase market is expected to reach USD 12 billion, growing at a CAGR of around 9% from 2023 to 2036[3].

Regional and Application-Specific Growth

  • Ophthalmology: There is a growing trend for hyaluronidase in ophthalmology, particularly for improved surgical outcomes[5].
  • Orthopedics and Veterinary Medicine: Emerging applications in orthopedics for post-operative recovery and in veterinary medicine for animal care are also anticipated to drive market growth[5].

Challenges and Opportunities

Regulatory Challenges

Stringent approval processes and regional disparities in the availability and distribution of hyaluronidase products are significant challenges affecting market growth[5].

Market Opportunities

  • Identifying Growth Trends: Investigating hyaluronidase applications in ophthalmology, orthopedics, and veterinary medicine presents lucrative opportunities for market expansion[5].
  • Efficient Pricing Strategies: Achieving efficient pricing strategies amid variability in insurance coverage is crucial for market growth[5].

Conclusion

Hyaluronidase is a versatile enzyme with expanding applications across various medical fields. Recent clinical trials and FDA approvals highlight its efficacy in cancer treatment, particularly in multiple myeloma and solid tumors. The market is poised for significant growth, driven by technological advancements, increasing prevalence of chronic diseases, and strategic collaborations.

Key Takeaways

  • Hyaluronidase has been approved for new indications in multiple myeloma and solid tumors.
  • The global hyaluronidase market is expected to grow substantially, reaching USD 2.62 billion by 2030.
  • Key growth drivers include the increasing prevalence of chronic diseases and technological advancements.
  • Dermatology and chemotherapy segments are significant contributors to the market.
  • Regulatory challenges and regional disparities need to be addressed for sustained market growth.

FAQs

What is hyaluronidase used for in medical treatments?

Hyaluronidase is used to break down hyaluronic acid, a component of the extracellular matrix, and has applications in cosmetic treatments, cancer therapy, ophthalmic solutions, and more.

What is the current market size of the hyaluronidase market?

The global hyaluronidase market was estimated at USD 909.5 million in 2022[2].

What are the key growth drivers for the hyaluronidase market?

Key growth drivers include the increasing prevalence of chronic diseases, technological advancements, and strategic collaborations between healthcare providers and biotech firms[3][5].

What are the main segments driving the hyaluronidase market?

The main segments include dermatology, chemotherapy, and emerging applications in ophthalmology and orthopedics[2][5].

What are the challenges facing the hyaluronidase market?

Challenges include regulatory hurdles, regional disparities in product availability, and inadequate reimbursement policies[5].

Sources

  1. American Association for Cancer Research. A New Multiple Myeloma Indication for Daratumumab and Hyaluronidase-fihj.
  2. Grand View Research. Hyaluronidase Market Size & Share Analysis Report, 2030.
  3. Research Nester. Hyaluronidase Market Size & Share, Growth Analysis 2036.
  4. Pharmacy Times. FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Use in Patients With Solid Tumors.
  5. 360iResearch. Hyaluronidase Market Size & Share 2025-2030.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.